Our focus is to maximize returns on mid-sized specialty assets through strategic investment and development processes.

Our Focus

Integrity, innovation, and patient-centricity are at the core of our approach, guiding our business decisions.

Our Values

We implement innovative strategies to assess and elevate the value of specialty pharmaceuticals in the market.

- 35+ years executive experience in life sciences
- Track record of creating growth with acquired assets
- Multiple successful acquisitions, financings, exits
- 25+ years life science experience
- Chief Legal Officer roles in multiple companies
- Multiple successful financings, IPOs, and M&A deals
- Management experience in building teams customized to the special needs of individual assets… no “cookie-cutter” approaches
- Services are either internally staffed or managed via experienced external third-parties.
- 25+ years life science experience
- Senior level commercial roles in oncology
- Developed and executed commercial strategies at global, regional and local level
- 30+ years life science experience
- Extensive clinical experience in medical oncology
- Leadership roles in medical affairs and clinical development for both solid tumor and heme assets
- 30+ years life science experience
- Ex FDA
- Senior executive experience at various biotech companies
- 15+ years life science experience
- Corporate Development roles in Pharma & Biotech
- Extensive finance and accounting experience

- Former CEO of Spectrum where he developed and launched Rolvedon.
- Former VP of Sales at Amgen where he developed and launched Neulasta, Epogen and Neupogen.
- Dr. Levy serves as the director of hematologic malignancies research at Texas Oncology.
- Dr. Levy specializes in hematology, including lymphoma, myeloma, and leukemia.
- Dr. Levy also served on the faculty at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- CEO of Carolina Blood and Cancer Care Associates.
- Dr. Patel is a full time practicing medical oncologist, board certified in Hematology, Oncology, and Internal Medicine.
- He is vice president for the Community Oncology Alliance (COA).
- He is also a member of the CPC committee for the ASCO and NCQA.
- He has been an advisor for the large payers including DHHS (SC), Palmetto GBA.
- He also serves on an advisory board for Medicaid HMOs.
- He also has extensive experience on revenue cycle management in oncology and he co-founded a large RCM company that started with 4 employees and now has over 700 employees.